Skip to main content
MAIA Biotechnology, Inc. logo

MAIA Biotechnology, Inc. — Investor Relations & Filings

Ticker · MAIA ISIN · US5526411021 US Manufacturing
Open in API
Filings indexed 456 across all filing types
Latest filing 2024-03-25 Capital/Financing Update
Country US United States of America
Listing US MAIA

About MAIA Biotechnology, Inc.

https://maiabiotech.com/

MAIA Biotechnology, Inc. is a clinical-stage immuno-oncology company focused on the development and commercialization of targeted therapies for cancer. The company develops potential first-in-class drugs with novel mechanisms of action, specializing in telomere-targeting agents. Its therapeutic approach utilizes immunotherapies designed to target telomeres in cancer cells. The company's pipeline products are currently under clinical investigation.

Recent filings

Filing Released Lang Actions
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 25, 2024, by MAIA Biotechnology, Inc. The content describes an increase in the maximum aggregate offering price of shares under an At The Market Offering Agreement, which is a financing activity. The document includes a legal opinion related to the offering and does not contain financial statements or detailed financial performance data. The length is 3573 characters, which is relatively short and focused on a specific capital raising event. Therefore, this filing is best classified as a Capital/Financing Update (CAP).
2024-03-25 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) under a registration statement on Form S-3. It updates and amends a prior prospectus related to an At The Market Offering Agreement for common stock sales. The text focuses on the terms of the offering, the amount of shares eligible to be sold, and market value details. It is not a full financial report, earnings release, or management discussion, but rather a capital raising disclosure. The document length is 3654 characters, which is relatively short and typical for a prospectus supplement. This type of filing corresponds to a Capital/Financing Update (CAP) as it provides updates on the company's fundraising and capital structure changes.
2024-03-25 English
10-K
Annual Report FY 2023
2024-03-21 English
Regulatory Filings 2024
Regulatory Filings
2024-03-21 English
PRIMARY DOCUMENT
Director's Dealing
2024-03-18 English
PRIMARY DOCUMENT
Director's Dealing
2024-03-16 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.